Key points are not available for this paper at this time.
Risks and rewards change during the life cycle of a drug. In the innovation period, drug companies invest in developing new products but cannot sell them. Newly approved drugs initially have exclusivity and enter the monopoly period, which is followed by the competitive period, when branded drugs compete with generics. The influence of policies on financial incentives in each period is described.
Khullar et al. (Wed,) studied this question.